

Benjamin Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/955138/publications.pdf>

Version: 2024-02-01

25
papers

418
citations

1163117

8
h-index

1058476

14
g-index

25
all docs

25
docs citations

25
times ranked

886
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated Genomic Analysis Identifies <i>UBTF</i> Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 194-207.	5.0	38
2	Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2022, , .	2.5	6
3	Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. <i>Blood Advances</i> , 2021, 5, 1437-1441.	5.2	15
4	ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth. <i>Nature Chemical Biology</i> , 2021, 17, 856-864.	8.0	49
5	Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10002-10002.	1.6	0
6	CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. <i>Blood Advances</i> , 2021, 5, 4963-4968.	5.2	4
7	EZH2-Mediated MHC Class II Silencing Drives Immune Evasion in AML with t(16;21) (<i>FUS-ERG</i>). <i>Blood</i> , 2021, 138, 374-374.	1.4	0
8	Targeting FOLR1 in High-Risk CBF2AT3-GLIS2 AML with Stro-002 FOLR1-Directed Antibody-Drug Conjugate. <i>Blood</i> , 2021, 138, 209-209.	1.4	1
9	<i>Nf1</i> -Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2382-2395.	4.1	3
10	Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice. <i>Blood</i> , 2020, 135, 1772-1782.	1.4	18
11	Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2025-2037.	7.2	27
12	Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. <i>Journal of Clinical Investigation</i> , 2020, 130, 863-876.	8.2	36
13	Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 31-32.	1.4	0
14	Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
15	Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 28-29.	1.4	0
16	Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts. <i>Blood</i> , 2020, 136, 20-21.	1.4	1
17	Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias. <i>PLoS Genetics</i> , 2019, 15, e1008168.	3.5	5
18	Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10033-10033.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 913-913.	1.4	0
20	KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. <i>Cell</i> , 2017, 168, 817-829.e15.	28.9	148
21	Resistant T-Cell Acute Lymphoblastic Leukemias That Emerge after In Vivo Treatment with Dexamethasone Frequently Down-Regulate Glucocorticoid Receptor Protein Expression. <i>Blood</i> , 2016, 128, 753-753.	1.4	7
22	Response and Resistance to Bromodomain Inhibition in AML Driven By Hyperactive Ras Signaling. <i>Blood</i> , 2016, 128, 1654-1654.	1.4	0
23	Risk Factors for Graft Failure with Busulfan/Fludarabine-Based Conditioning in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Nonmalignant Disorders. <i>Blood</i> , 2014, 124, 1155-1155.	1.4	0
24	Mutant <i>Ikzf1</i> , <i>Kras</i> ^{G12D} , and <i>Notch1</i> cooperate in T lineage leukemogenesis and modulate responses to targeted agents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 5106-5111.	7.1	60
25	Expressing N-RasG12D from the Endogenous Promoter Induces Myeloproliferative Disease (MPD) and Cooperates with Retroviral Insertional Mutagenesis (RIM) To Generate Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007, 110, 1616-1616.	1.4	0